Quick Comparison
| Livagen | VIP | |
|---|---|---|
| Half-Life | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure | 1-2 minutes (rapidly degraded by peptidases) |
| Typical Dosage | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson cycling rather than continuous use. | Intranasal (preferred): 50 mcg per spray, one to four times daily. Subcutaneous: 50-100 mcg once daily. CIRS protocol (Shoemaker): intranasal delivery for brain and sinus access. Treatment duration varies by condition. |
| Administration | Oral capsule or subcutaneous injection (cycled) | Intranasal spray or subcutaneous injection |
| Research Papers | 5 papers | 32 papers |
| Categories |
Mechanism of Action
Livagen
Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.
Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.
As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.
VIP
Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide that belongs to the secretin/glucagon superfamily. It is widely distributed throughout the body — found in neurons of the central and peripheral nervous systems, immune cells, and the gastrointestinal tract — and acts through two G protein-coupled receptors: VPAC1 (expressed broadly) and VPAC2 (more restricted to CNS and immune tissue). Both receptors couple to Gs proteins, activating adenylyl cyclase and raising intracellular cAMP.
VIP's vasodilatory effect is among the most potent in the body. It relaxes vascular, airway, and gastrointestinal smooth muscle by activating cAMP/PKA signaling, which phosphorylates myosin light chain kinase and reduces calcium sensitivity in smooth muscle cells. In the pulmonary vasculature, this produces bronchodilation and reduced pulmonary artery pressure. In cerebral vasculature, VIP is a key regulator of blood flow.
The immunomodulatory effects are particularly relevant for its use in chronic inflammatory response syndrome (CIRS). VIP powerfully suppresses the Th1 (pro-inflammatory) immune response while promoting Th2 and regulatory T cell (Treg) differentiation. It inhibits macrophage production of TNF-α, IL-6, IL-12, and nitric oxide, and suppresses dendritic cell maturation and antigen presentation. This immune-balancing effect makes VIP valuable in conditions characterized by chronic Th1/Th17 immune dysregulation, such as mold illness/CIRS. In the brain, VIP is neuroprotective — it upregulates BDNF and activity-dependent neuroprotective protein (ADNP), supports circadian rhythm regulation in the suprachiasmatic nucleus, and protects neurons from inflammatory and oxidative damage. The extremely short plasma half-life (1-2 minutes) necessitates intranasal delivery for CNS effects, bypassing the blood-brain barrier through olfactory and trigeminal nerve transport.
Risks & Safety
Livagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; long-term safety in the context of pre-existing liver disease is not established.
Rare
allergic reactions. Like other Khavinson bioregulators, the evidence base is significantly thinner than the marketing suggests.
VIP
Common
diarrhea, widened blood vessels and facial flushing, nasal congestion when used as a nasal spray, mild low blood pressure.
Serious
significant drop in blood pressure in sensitive people or at high doses; fast heart rate from the body's response to widened blood vessels.
Rare
severe allergic reactions, airway narrowing. Very short half-life naturally limits how much reaches the rest of the body.
Full Profiles
Livagen →
A Khavinson tripeptide (Lys-Glu-Asp) developed in Russia as a tissue-specific bioregulator targeting the liver. Promoted for supporting liver regeneration, age-related liver decline, and as part of broader anti-ageing protocols. Sits in the same family as epithalon (pineal), cortagen (brain), and pinealon (pineal/brain). Most evidence is from Russian preclinical work — rigorous Western clinical trials are essentially nonexistent.
VIP →
A natural peptide found throughout the body, especially in the nervous system, gut, and lungs. It widens blood vessels, calms inflammation, and helps balance the immune system. Most studied for chronic inflammatory conditions (like mold illness) and high blood pressure in the lungs, where it tones down excessive inflammatory signaling. People use it for CIRS, mold illness, and similar conditions.